FDA advisers stated that two single-agent long-acting beta2 agonist inhalers should have their pediatric asthma indications discontinued, reported Reuters.
FDA advisers stated that two single-agent long-acting beta2 agonist inhalers should have their pediatric asthma indications discontinued, reported Reuters.
According to the panel, the two drugs - salmeterol and formoterol-carry high risks for asthma - related complications and death that are not outweighed by a relatively small apparent health benefit when the drugs are used without a steroid.
The majority of the panel voted against the age 12 to 17 indication, and voted unanimously against the age 4 to 11 indication, for both salmeterol and formoterol.
As the FDA will consider the recommendations and make an official announcement regarding their use and indications, agency officials stated that patients should not stop taking any prescribed asthma medications without consulting a physician.
Anger hurts your team’s performance and health, and yours too
October 25th 2024Anger in health care affects both patients and professionals with rising violence and negative health outcomes, but understanding its triggers and applying de-escalation techniques can help manage this pervasive issue.